N-(3-BROMO-2,6-DINITRO-4-(TRIFLUOROMETHYL)PHENYL)-3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KABRNACGQVFUTJ-UHFFFAOYSA-N
Smiles	[O-][N+](=O)c1cc(c(Br)c(c1Nc2ncc(cc2Cl)C(F)(F)F)[N+](=O)[O-])C(F)(F)F
InChI	InChI=1S/C13H4BrClF6N4O4/c14-8-5(13(19,20)21)2-7(24(26)27)9(10(8)25(28)29)23-11-6(15)1-4(3-22-11)12(16,17)18/h1-3H,(H,22,23)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H4BrClF6N4O4
Molecular Weight	509.54
AlogP	5.85
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	6.0
Polar Surface Area	116.56
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Botryotinia fuckeliana inoculated on compound pre-treated one-leaf stage cucumber seedlings assessed as prevention of leaf lesions measured 3 days after inoculation	Botryotinia fuckeliana	16.0 ppm
Fungicidal activity against Rhizoctonia solani infected in 24 hr compound pre-treated Oryza sativa cv. Chukyoasahi assessed as disease control measured after 10 days	Rhizoctonia solani	63.0 ppm
Fungicidal activity against Podosphaera fuliginea infected in 24 hr compound pre-treated cucumber plant assessed as disease control measured after 10 days	Podosphaera fuliginea	63.0 ppm
Fungicidal activity against Magnaporthe oryzae infected in 24 hr compound pre-treated Oryza sativa cv. Chukyoasahi assessed as disease control measured after 10 days	Magnaporthe oryzae	16.0 ppm

Cross References

Resources	Reference
ChEMBL	CHEMBL2268597
PubChem	158535

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).